General Information of Drug (ID: DMREVX9)

Drug Name
(5R,6S)-5,6-bis(benzyloxy)cyclohex-2-enone Drug Info
Synonyms CHEMBL378672; (5R,6S)-5,6-bis(benzyloxy)cyclohex-2-enone; GS416
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
11809004
TTD Drug ID
DMREVX9

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Approved Drug(s)
Drug(s) Targeting Presenilin 1 (PSEN1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
(S)-FLURBIPROFEN DMF2O4T Myalgia FB56.2 Preregistration [2]
R-flurbiprofen DMFIVSR N. A. N. A. Phase 2 [2]
(5R,6S)-6-(benzyloxy)-5-methoxycyclohex-2-enone DMHG7MU Discovery agent N.A. Investigative [1]
Drug 311951 DMXTCJ1 Discovery agent N.A. Investigative [3]
Drug 311383 DM5QUJV Discovery agent N.A. Investigative [3]
1-benzoyl-2-benzyl-1,2-dihydropyridin-3(6H)-one DMF9X2T Discovery agent N.A. Investigative [1]
(2S,3R)-2-(benzyloxy)-3-methoxycyclohexanone DMJE83O Discovery agent N.A. Investigative [1]
Drug 311952 DM27ILS Discovery agent N.A. Investigative [3]
Drug 311440 DMOIFBK Discovery agent N.A. Investigative [3]
1-Chloro-4-(1-phenyl-cyclohexanesulfonyl)-benzene DM13HGN Discovery agent N.A. Investigative [4]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Presenilin 2 (PSEN2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
(S)-FLURBIPROFEN DMF2O4T Myalgia FB56.2 Preregistration [2]
R-flurbiprofen DMFIVSR N. A. N. A. Phase 2 [2]
(5R,6S)-6-(benzyloxy)-5-methoxycyclohex-2-enone DMHG7MU Discovery agent N.A. Investigative [1]
Drug 311951 DMXTCJ1 Discovery agent N.A. Investigative [3]
Drug 311383 DM5QUJV Discovery agent N.A. Investigative [3]
1-benzoyl-2-benzyl-1,2-dihydropyridin-3(6H)-one DMF9X2T Discovery agent N.A. Investigative [1]
(2S,3R)-2-(benzyloxy)-3-methoxycyclohexanone DMJE83O Discovery agent N.A. Investigative [1]
Drug 311952 DM27ILS Discovery agent N.A. Investigative [3]
Drug 311440 DMOIFBK Discovery agent N.A. Investigative [3]
1-Chloro-4-(1-phenyl-cyclohexanesulfonyl)-benzene DM13HGN Discovery agent N.A. Investigative [4]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Gamma-secretase (GS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nirogacestat DMUP5Z0 Desmoid tumour 2F7C Approved [5]
(S)-FLURBIPROFEN DMF2O4T Myalgia FB56.2 Preregistration [2]
AMG 386 DMQJXL4 Breast cancer 2C60-2C65 Phase 3 [6]
Semagacestat DML83IW Parkinson disease 8A00.0 Phase 3 [7]
R-flurbiprofen DMFIVSR N. A. N. A. Phase 2 [2]
MK-0752 DMLTAES Alzheimer disease 8A20 Phase 2 [8]
BMS-708163 DM51LTG Alzheimer disease 8A20 Phase 2 [9]
CHF-5074 DMTE071 Alzheimer disease 8A20 Phase 2 [10]
RO-4929097 DMXA6B3 Breast cancer 2C60-2C65 Phase 2 [11]
AL102 DMCTWIB Desmoid tumour 2F7C Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Gamma-secretase (GS) TT9W8GU APH1A_HUMAN; APH1B_HUMAN; PEN2_HUMAN; NICA_HUMAN; PSN1_HUMAN Inhibitor [1]
Presenilin 1 (PSEN1) TTZ3S8C PSN1_HUMAN Inhibitor [1]
Presenilin 2 (PSEN2) TTWN3F4 PSN2_HUMAN Inhibitor [1]

References

1 Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3813-6.
2 The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23.
3 Discovery of a Subnanomolar helical D-tridecapeptide inhibitor of gamma-secretase. J Med Chem. 2004 Jul 29;47(16):3931-3.
4 Aryl sulfones: a new class of gamma-secretase inhibitors. Bioorg Med Chem Lett. 2005 May 16;15(10):2685-8.
5 Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014.J Pharmacol Exp Ther.2010 Jul;334(1):269-77.
6 Clinical pipeline report, company report or official report of Roche (2009).
7 A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Jul 25;369(4):341-50.
8 Determination of the gamma-secretase inhibitor MK-0752 in human plasma by online extraction and electrospray tandem mass spectrometry (HTLC-ESI-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Sep 1;878(25):2348-52.
9 Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol. 2012 Nov;69(11):1430-40.
10 CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease.Br J Pharmacol.2009 Mar;156(6):982-93.
11 Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol. 2012 Jul 1;30(19):2348-53.
12 Clinical pipeline report, company report or official report of Ayala Pharmaceuticals.